Editor Profile
Najam Sharif
University/Organization: Santen Inc, USA
Country: United States
Biography
Dr. Naj Sharif is a graduate of Southampton University, England (UK) where he received his BSc (Joint Honors: Biochemistry and Physiology) and his PhD (Neuroscience). Dr. Sharif has been in the pharmaceutical industry for >30-years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Executive Director, R&D Division). Dr. Sharif’s 22-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan®, Patanol®, Simbrinza®, Izba® and Pazeo® to treat glaucoma/ocular hypertension and ocular allergies.
Dr. Sharif was recently elected as a Fellow of ARVO (FARVO), and was also honored as the first recipient of the inaugural Dr. Roger Vogel award for pharmaceutical research presented by the ARVO Foundation. He has been an organizer, chairman and invited speaker at numerous global symposia and workshops. Dr. Sharif serves on the editorial boards of numerous scientific journals, is an adjunct professor at several universities, and a thesis advisor for MS- and PhD-level students. He has published >190 scientific articles and edited 2 Neuroscience books. Dr. Sharif is also a prolific inventor, having secured >22 issued US and EU patents on ocular cell-lines and small molecules to treat human diseases of the CNS and the eye.
Research Interest
His research interest includes ocular function/disease, Prostanoid release, Ocular hypertension, Glaucoma, Ocular allergies, Neuroprotection, Receptor pharmacology, Drug discovery and development.
Scientia Ricerca is licensed and content of this site is available under a Creative Commons Attribution 4.0 International License.